Prescient Therapeutics (PTX.AX) Osake Kurssi

Prescient Therapeutics Kurssi

ASX·SULJETTU
0,05
​
Markkina suljettu

Viimeisten 18 vuoden aikana Prescient Therapeuticsn liikevaihto kasvoi 5,9 % vuodessa ja ylsi 4,36 M AUD:een. Prescient Therapeuticsn nettomarginaali −168,1 % on noussut verrattuna −350,1 %:iin muutama vuosi sitten.

Prescient Therapeutics osakekurssi

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Prescient Therapeutics liiketoimintamalli ja osakeanalyysi

Prescient Therapeutics Ltd on australialainen biotekniikkaan erikoistunut yritys, joka keskittyy uusien syöpälääkkeiden kehittämiseen. Yritys perustettiin vuonna 2006. Sen liiketoimintamalli perustuu nykyaikaisten teknologioiden ja tutkimustulosten hyödyntämiseen innovatiivisten syövän hoidon ratkaisujen luomiseksi. Prescient Therapeutics toimii kahdessa segmentissä: lääkekehitys ja tutkimuspalvelut. Yritys tekee tiivistä yhteistyötä johtavien tutkijoiden ja terveydenhuollon laitosten kanssa hyödyntäkulleen syöpätutkimuksen viimeisimpiä edistysaskeleita ja tuodakseen uusia lääkkeitä markkinoille. Yksi sen tuotteista, PTX-200, on uusi proteiinikinaasi CK2:n estäjä, joka on osoittanut tehokkuutta kliinisissä kokeissa eri syöpätyypeissä. Toinen merkittävä tuote on OmniCAR, seuraavan sukupolven CAR-T-soluhoidolla, joka mahdollistaa syöpäsolujen valikoivan tunnistamisen ja tuhoamisen. Prescient Therapeutics pyrkii vahvistamaan asemaansa innovatiivisten syövän hoitomenetelmien johtavana tarjoajana tiukan validointistrategian ja lääkäreiden sekä potilaiden kanssa tehtävän yhteistyön kautta. Yritys on edistynyt merkittävästi uusien syöpälääkkeiden kehityksessä, omistaen lukuisia patentteja ja solmiutua kumppansuhteita johtavien terveydenhuollon laitosten kanssa. Sen tavoitteena on täyttää syöpäpotilaiden tyydyttämättömät tarpeet ja luoda parempi tulevaisuus syövän hoidolle.

Usein kysytyt kysymykset Prescient Therapeutics -osakkeesta

Prescient Therapeutics Ltd is primarily active in the biotechnology and healthcare industries.

Prescient Therapeutics Ltd is a biotechnology company focused on developing novel targeted therapies to meet unmet medical needs. The company's business model revolves around identifying promising drug candidates, conducting preclinical and clinical studies, and seeking regulatory approvals for commercialization. With a strong emphasis on precision medicine, Prescient Therapeutics aims to improve patient outcomes by developing personalized therapies that target specific disease pathways. By leveraging its expertise in drug discovery and development, the company endeavors to bring innovative treatments to market, addressing critical medical challenges and creating value for its stakeholders.

The main competitors of Prescient Therapeutics Ltd in the market include companies such as Novartis AG, Incyte Corporation, and Incyte Biosciences. These companies operate in the same pharmaceutical and biotechnology industry, offering innovative solutions and treatments for various diseases and medical conditions. While Novartis AG is a global leader in pharmaceuticals, Incyte Corporation and Incyte Biosciences are renowned biopharmaceutical companies known for their expertise in oncology and immunology research. Prescient Therapeutics competes with these companies in terms of research and development, product offerings, market share, and overall industry presence.

Prescient Therapeutics Ltd. is a biotechnology company based in Australia. Formed in 2013, the company focuses on developing innovative cancer treatments. Prescient Therapeutics aims to deliver personalized medicine options to patients through its unique platform that identifies and targets specific gene mutations responsible for various types of cancers. The company has a team of experienced scientists and clinicians dedicated to advancing its pipeline of drug candidates. With a strong emphasis on research and development, Prescient Therapeutics continues to explore new therapeutic avenues and collaborations to address unmet medical needs in oncology.

Prescient Therapeutics Ltd has achieved several significant milestones. The company successfully completed a phase 1b study for its lead compound PTX-200, demonstrating its safety and tolerability. Prescient also received regulatory approval to initiate a phase 2b study evaluating PTX-200 in patients with relapsed or refractory acute myeloid leukemia (AML). Furthermore, Prescient Therapeutics secured a partnership with Peter MacCallum Cancer Centre to conduct the phase 2 clinical trial. The company has also expanded its intellectual property portfolio, with multiple patent applications filed for innovative therapies. Prescient Therapeutics continues to make strides in the development of new and effective treatments for cancer patients.

Prescient Therapeutics Ltd is primarily present in Australia.

Prescient Therapeutics Ltd is a leading biotech company dedicated to developing innovative cancer treatments. Their values and corporate philosophy are centered around advancing medical breakthroughs to improve patient outcomes. With a focus on precision medicine, Prescient Therapeutics aims to deliver targeted therapies tailored to patients' unique genetic profiles. They prioritize collaboration with leading researchers and clinicians to accelerate the development and commercialization of cutting-edge treatments. As a patient-centric organization, Prescient Therapeutics is committed to ensuring safety, efficacy, and accessibility of their treatments. By combining scientific expertise, ethical practices, and a passion for improving lives, Prescient Therapeutics is revolutionizing the field of oncology.

5 analyytikkoa arvioi tällä hetkellä Prescient Therapeutics-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.

Nykyisellä valuuttakurssilla Prescient Therapeutics-osake noteerataan hintaan 0,03 EUR (0,05 AUD).

Prescient Therapeutics-osake (PTX.AX) on listattuna 2 pörssissä, muun muassa: ASX (PTX.AX).

Prescient Therapeutics Ltd is an Australian biopharmaceutical company focused on developing novel cancer therapies. The company's business model includes research and development, clinical trials, and partnerships with other companies. Prescient Therapeutics dedicates a significant portion of its resources to researching and developing new cancer drugs. The company relies on innovative technologies and strives to develop groundbreaking therapeutic approaches. Prescient Therapeutics also has a strong research pipeline, enabling the company to advance the development of new drugs. The company conducts clinical trials to evaluate the efficacy of its medications. These trials are led by experienced clinicians and aim to assess the safety and effectiveness of new therapies. The results from these studies are then used to improve the treatment of cancer patients. Prescient Therapeutics also collaborates with other companies to advance its research and development. The company has partnerships with other biopharmaceutical companies to jointly develop new technologies and therapies. Through these partnerships, the company can leverage its resources and accelerate its research. Currently, the company has two main products on the market, PTX-100 and PTX-200. PTX-100 is a small molecule that can inhibit the Hsp90 protein, which plays a significant role in cancer development. PTX-100 is currently being tested in clinical trials for the treatment of myeloma and other types of cancer. On the other hand, PTX-200 is an antibody drug that targets the ENPP3 protein, which is highly upregulated in many types of cancer. PTX-200 is still in the preclinical development phase but has shown promising results in animal studies. In conclusion, Prescient Therapeutics Ltd is a company dedicated to developing new cancer therapies. The company is working on innovative treatment approaches to improve the care of cancer patients. Their business model includes research and development, clinical trials, and partnerships with other companies. With their products PTX-100 and PTX-200, the company has already achieved promising results and is expected to bring more innovative therapies to the market in the future.

Liikevaihtoa ei voida laskea Prescient Therapeutics:lle tällä hetkellä.

voitto Prescient Therapeutics on −7,00 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Prescient Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −8,26. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Prescient Therapeutics-osakkeen arvostusta.

P/S-suhdetta ei voida laskea Prescient Therapeutics:lle tällä hetkellä.

Prescient Therapeutics:n Eulpool-laatuscore on 3/10.

Prescient Therapeutics:n ISIN on AU000000PTX3. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Prescient Therapeutics:n WKN on A12GQZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Prescient Therapeutics:n ticker on PTX.AX. Tämä pörssinoteeraus käytetään Prescient Therapeutics-osakkeiden kauppaan pörssissä.

Käypä arvoTerminal
0,05 AUD
Yliarviointia/AliarviointiaTerminal
Reilusti arvostettu
Toimiala
Bioteknologia
Osakkeiden lukumäärä
Työntekijät
Liikevaihdon kasvu Ø 5 vuotta
EBIT-kasvu Ø 5 vuotta
Nettotulon kasvu Ø 5 vuotta
Maa
Australia
Valuutta
AUD
Julkinen listaus
12.6.2013
ISIN
AU000000PTX3
CUSIP
Q7737S105
SEDOL
BTGCRQ7
Markkina-arvo
44,29 M AUDMicro Cap
52 viikon vaihteluväli
PEG-suhde
0,38
P/E-suhde
P/Ee-suhde 2027
−0,68
P/Ee-suhde 2028
5,44
P/Ee-suhde 2033
−2,39
P/Ee-suhde 2034
−1,80
P/S-suhde
P/Se-suhde
219,07
EV/EBIT
—
P/B-suhde
3,12
ROE (oman pääoman tuotto)
ROA (varojen tuotto)
ROCE (pääomakäytön tuotto)
ROIC (sijoitetun pääoman tuotto)
−48,55 %
Viimeksi päivitetty 22.11.2026 klo 12.36

Prescient Therapeutics Ticker

ASX · PTX.AXOTC · PSTTF

Prescient Therapeutics FIGI

PTX:AU · BBG000J4RZB1PTX:AT · BBG000J4RZJ3PTX:AH · BBG002F3GQP0PSTTF:US · BBG00GMB7784PSTTF:PQ · BBG00GMB77N7PSTTF:UV · BBG00GMB77P5PTXAUD:EP · BBG00Y449GM3PTXAUD:EZ · BBG00Y449GP0PTXAUD:XS · BBG00Y449GQ9PTXAUD:X2 · BBG00Y449GR8PTXAUD:XH · BBG00Y449GT6PTXAUD:XF · BBG00Y449GW2